Log in

NASDAQ:ACIU - AC Immune Stock Price, Forecast & News

$8.52
+0.07 (+0.83 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$8.39
Now: $8.52
$8.64
50-Day Range
$8.20
MA: $9.07
$9.89
52-Week Range
$3.89
Now: $8.52
$10.14
Volume143,116 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio12.17
Dividend YieldN/A
BetaN/A
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:ACIU
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees92
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.


AC Immune (NASDAQ:ACIU) Frequently Asked Questions

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) released its quarterly earnings data on Wednesday, November, 13th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.08. The firm earned $33.90 million during the quarter, compared to analysts' expectations of $31.50 million. View AC Immune's Earnings History.

When is AC Immune's next earnings date?

AC Immune is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for AC Immune.

What price target have analysts set for ACIU?

1 brokers have issued twelve-month target prices for AC Immune's shares. Their forecasts range from $11.00 to $11.00. On average, they expect AC Immune's share price to reach $11.00 in the next year. This suggests a possible upside of 29.1% from the stock's current price. View Analyst Price Targets for AC Immune.

What is the consensus analysts' recommendation for AC Immune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AC Immune.

Has AC Immune been receiving favorable news coverage?

News coverage about ACIU stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AC Immune earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for AC Immune.

Are investors shorting AC Immune?

AC Immune saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 452,700 shares, an increase of 11.4% from the January 15th total of 406,200 shares. Based on an average trading volume of 133,400 shares, the short-interest ratio is currently 3.4 days. Approximately 1.4% of the company's shares are short sold. View AC Immune's Current Options Chain.

What other stocks do shareholders of AC Immune own?

Who are AC Immune's key executives?

AC Immune's management team includes the folowing people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 61)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 41)
  • Mr. Piergiorgio Donati, Head of Technical Operations & Program Management (Age 48)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 61)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 48)

When did AC Immune IPO?

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (16.79%), Renaissance Technologies LLC (0.72%), Acadian Asset Management LLC (0.48%), Marshall Wace LLP (0.20%), FMR LLC (0.10%) and Alpine Woods Capital Investors LLC (0.06%).

Which institutional investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Tower Research Capital LLC TRC and ProShare Advisors LLC.

Which institutional investors are buying AC Immune stock?

ACIU stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, BVF Inc. IL, Alpine Woods Capital Investors LLC, Oxford Asset Management LLP, Trexquant Investment LP and Spark Investment Management LLC.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $8.52.


MarketBeat Community Rating for AC Immune (NASDAQ ACIU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  437
MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel